Anti-VLA4
Anti-VLA4 Brand names, Anti-VLA4 Analogs
Anti-VLA4 Brand Names Mixture
- No information avaliable
Anti-VLA4 Chemical_Formula
No information avaliable
Anti-VLA4 RX_link
http://www.rxlist.com/cgi/generic3/tysabri.htm
Anti-VLA4 fda sheet
Anti-VLA4 msds (material safety sheet)
Anti-VLA4 Synthesis Reference
Sequence listed in Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997;8(1):3-16
Anti-VLA4 Molecular Weight
No information avaliable
Anti-VLA4 Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Anti-VLA4 H2O Solubility
No information avaliable
Anti-VLA4 State
Liquid
Anti-VLA4 LogP
No information avaliable
Anti-VLA4 Dosage Forms
Solution (IV Infusion)
Anti-VLA4 Indication
For treatment of multiple sclerosis
Anti-VLA4 Pharmacology
In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain.
Anti-VLA4 Absorption
No information avaliable
Anti-VLA4 side effects and Toxicity
No information avaliable
Anti-VLA4 Patient Information
BIOD00083.html
Anti-VLA4 Organisms Affected
Humans and other mammals
